Background Mantle cell lymphoma (MLC) is nowadays an aggressive and incurable Non-Hodgkin's lymphoma, characterized by multiple relapses.The persistent activation of B-cell receptor pathway is critical for pathogenesis. Ibrutinib is a potent covalent inhibitor of Bruton's tyrosine kinase (BTK) that...
The FDA approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) treated with at least 2 prior lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor. The approval of this CD19-direc...
Introduction: Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult‐to‐treat population with poor outcome, where no standard therapy exists. There is a paucity of large‐scale data in relapsed or refractory (r/r) MCL. Methods: MANTLE‐FIRST, an ...
Three-year Follow-Up of KTE-X19 in patients with Relapsed/Refractory Mantle Cell Lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–67. Article CAS PubMed Google Scholar Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, et al. A phase 1...
Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma. Simon Rule, MD Treatment with ibrutinib (Imbruvica) sparked more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma (MCL), a phase III ...
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial Lenalidomide–rituximab therapy is effective in grade 1–2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), .....
Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.METHODS:In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until ...
SummaryBackground Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed activity in many single-group studies in relapsed or refractory mantle cell lymphoma. The aim of this randomised study was to examine the efficacy and safety of lenalidomide versus best investi...
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential ofCalquenceas a treatment for people with relapsed or refractory mantle cell lymphoma, a life...
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial SummaryBackground Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed activity in many single-group studies in re...